Grant Pickering, Vaxcyte CEO
Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine
Vaxcyte shares $PCVX jumped more than 40% Tuesday morning on the heels of Phase 1/2 data for its 31-valent pneumococcal conjugate vaccine, VAX-31, being tested …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
